AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Key Terms

multi-omic assay medical

A multi-omic assay is a laboratory test that measures several kinds of biological information at once — such as DNA, RNA, proteins and small molecules — to build a more complete picture of how cells or tissues are functioning. For investors, these tests matter because they can improve the accuracy of diagnostics, speed drug development and reveal reliable biomarkers, acting like multiple camera angles that reduce uncertainty about a potential therapy or diagnostic’s performance and market potential.

spatial proteomics medical

Spatial proteomics maps which proteins are present and exactly where they sit within cells and tissues, combining a protein “inventory” with a location map. For investors it matters because knowing the physical location of disease-related proteins helps identify better drug targets, improves diagnostic markers and reduces the risk of costly late-stage failures — like a city map that shows both who is working and where they are so planners can make smarter choices.

locoregional recurrence medical

Locoregional recurrence is when a disease, usually cancer, comes back in the same area where it started or in nearby tissues or lymph nodes after initial treatment. For investors, this matters because return of disease often means more treatment, higher costs, altered patient outcomes and changed demand for drugs, devices or services—think of a weed reappearing in the same garden patch, signaling the need for additional or different care that can affect a company’s financial outlook.

radiation therapy medical

Radiation therapy uses focused high-energy rays or particles to kill or shrink abnormal cells inside the body, often delivered from outside the body or by placing tiny sources near the target. Think of it like using a magnifying glass to concentrate sunlight on a small spot to remove a weed without digging up the whole garden. Investors watch radiation therapy because its effectiveness, side effects, regulatory approvals, equipment needs and reimbursement rules directly affect healthcare companies’ revenues, clinical trial outcomes and long-term costs.

hormone receptor-positive medical

A tumor described as hormone receptor-positive has cancer cells that carry proteins on their surface which hormones — most commonly estrogen or progesterone — can bind to and use like a key to stimulate growth. For investors this matters because it determines whether hormone-blocking drugs and specific diagnostic tests are likely to work, shaping treatment options, market demand, clinical trial strategies and the commercial outlook for related therapies.

HER2-negative medical

HER2-negative describes a cancer that does not have an excess of the HER2 protein on tumor cells; think of it as a door that lacks a specific lock that certain drugs are designed to fit. It matters to investors because it determines which therapies can work, how large the treatable patient group is, and the commercial and clinical prospects for drugs and trials targeting that subtype.

next-generation RNA sequencing medical

Next-generation RNA sequencing is a laboratory method that reads and counts all the active RNA messages in cells, producing a detailed snapshot of which genes are turned on or off. Investors care because it uncovers disease markers, patient subgroups, and drug effects much like a high-resolution camera reveals details a blurry picture misses, which can speed development, guide clinical trials, and create diagnostics or therapies with clearer commercial potential.

immune-microenvironment medical

The immune microenvironment is the mix of immune cells, signaling molecules and surrounding tissue right around a tumor or diseased area that together influence whether the body fights or tolerates the problem. It matters to investors because this local immune

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Novel Assay, Developed on Akoya PhenoImager HT Platform with Opal Chemistry, Becomes First to Predict Both Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer

LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)-- PreludeDx^® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager^® HT platform using Opal™ chemistry. This marks a significant milestone in the clinical translation of spatial proteomics.

The validation of AidaBREAST included 922 hormone receptor-positive, HER2-negative invasive breast cancer patients across four academic and clinical centers in the United States and Sweden, with a median follow-up of ~10 years. The study demonstrated the test to be both prognostic for 10-year locoregional recurrence risk and predictive for radiation therapy benefit, two capabilities not previously available to clinicians in a single assay for early-stage invasive breast cancer.

AidaBREAST leverages the PhenoImager HT platform and Opal chemistry to obtain spatial multiplex protein expression, which is then integrated with targeted next-generation RNA sequencing for comprehensive assessment of tumor biology.

“AidaBREAST harnesses the power of spatial biology and AI to provide unique insights into the tumor and immune-microenvironment not available from clinicopathology,” said Karuna Mittal, PhD, Senior Director of Research and Development at PreludeDx and co-author of the published study. "For the first time, oncologists have a tool that tells them not just how likely a patient is to recur, but whether radiation therapy is actually going to help that specific patient. That is a meaningful shift in how we can better inform treatment decisions."

"AidaBREAST is exactly the kind of scientific achievement that demonstrates what is possible when spatial proteomics is applied with rigor and clinical intent," said Everett Cunningham, Chief Executive Officer of Quanterix. "PreludeDx’s ability to develop a truly novel tool on our PhenoImager HT platform – that also performs reliably and reproducibly across multiple institutions and years of archived tissue, speaks to the immediate opportunity for spatial proteomics in clinical oncology."

AACR Annual Meeting 2026

Dr. Karuna Mittal will present the AidaBREAST study findings at the Quanterix booth 2028 at the AACR Annual Meeting 2026 on Tuesday, April 21st from 11:45 to 12:00 PM, with a focus on the role of spatial proteomics in locoregional recurrence risk assessment and radiation therapy decision-making. Attendees are invited to visit booth 2028 to learn more.

For more information visit: https://www.quanterix.com/events-conferences/aacr-american-association-for-cancer-research-annual-meeting-2026/

About AidaBREAST™ for Early-Stage Breast Cancer

AidaBREAST™ is the only risk assessment test for patients with stage I,IIa breast cancer that predicts radiation therapy benefit. The next-generation multi-omic assay developed by PreludeDx uses advanced spatial biology technology combining multiplex protein expression with targeted next-generation RNA sequencing to provide a comprehensive assessment of a patient’s tumor biology. Leveraging the power of artificial intelligence, the assay integrates these complex data to generate a patient’s individualized risk assessment for 10-year locoregional recurrence and predict their benefit from radiation therapy. This innovative approach enables physicians to move beyond traditional measures offering patients personalized results with new insights into recurrence risk and radiation therapy benefit. This new information helps patients and their physicians to make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company serving patients and physicians worldwide. Founded in 2009 with technology from the University of California San Francisco, PreludeDx is dedicated to developing precision breast cancer tools that impact treatment decisions. The company's mission is to provide innovative technologies that improve patient outcomes and reduce healthcare costs. Before making a treatment decision, Know Your Risk™, Know Your Benefit. For more information on how PreludeDx is making a difference for patients, please visit the Company's website: https://preludedx.com and follow us on X, LinkedIn, Instagram and Facebook.

About Quanterix

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa^® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,300 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company^®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,439 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue -- advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417416495/en/

Media Contact — PreludeDx
Martin Sandgren
Klover Communications
press@klovercommunications.com

Media Contact — Quanterix
media@quanterix.com

Investor Relations Contact — Quanterix
Joshua Young
jyoung@quanterix.com

Source: Quanterix Corporation